Linezolid 600 mg
Linezolid 600mg — the standard adult dose of the first-in-class oxazolidinone antibiotic. Inhibits bacterial protein synthesis at the initiation step by binding to 23S ribosomal RNA and preventing 70S initiation complex formation. Active against MRSA, VRE, MDR-TB, and penicillin-resistant S. pneumoniae. Near-100% oral bioavailability. See MIGHTYZOL™ Dry Syrup for full mechanism detail.
Adult dosing for serious gram-positive infections: MRSA pneumonia, skin and soft tissue infections, bacteraemia, and osteomyelitis; VRE infections; MDR-TB (as part of longer regimens); complicated skin infections unresponsive to first-line therapy. DPCO-regulated to ensure accessibility for long-course treatments.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
MIGHTYZOL™ 600 is the adult tablet companion to MIGHTYZOL™ Dry Syrup, completing the linezolid range within Seclis Labs' portfolio. DPCO regulation of this high-value reserve antibiotic is critically important — MDR-TB patients require 6–9 months of linezolid therapy, and unregulated pricing can make this treatment inaccessible. DPCO-compliance makes MIGHTYZOL™ 600 both a clinically and ethically sound choice for infectious disease specialists managing drug-resistant TB in both public and private settings.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.